Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plant Extracts | 3 | 2018 | 172 | 0.330 |
Why?
|
| Rhodiola | 3 | 2018 | 15 | 0.270 |
Why?
|
| Phytotherapy | 2 | 2018 | 53 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 663 | 0.200 |
Why?
|
| Genes, APC | 1 | 2002 | 10 | 0.190 |
Why?
|
| Lactones | 1 | 2002 | 26 | 0.190 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 45 | 0.190 |
Why?
|
| Isoenzymes | 1 | 2002 | 140 | 0.190 |
Why?
|
| Cell Respiration | 2 | 2018 | 21 | 0.180 |
Why?
|
| Leukopenia | 1 | 2019 | 16 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 276 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 121 | 0.150 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 124 | 0.150 |
Why?
|
| Neuroblastoma | 1 | 2018 | 52 | 0.140 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 56 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 85 | 0.130 |
Why?
|
| Phosphorylcholine | 1 | 2016 | 44 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2016 | 100 | 0.120 |
Why?
|
| Prodrugs | 1 | 2016 | 36 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2002 | 791 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 44 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1198 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 150 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2017 | 390 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 81 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 379 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 615 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 1471 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2015 | 158 | 0.100 |
Why?
|
| Polymers | 1 | 2016 | 325 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1311 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 310 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 525 | 0.080 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 17 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 29 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2010 | 64 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 70 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1364 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 281 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2018 | 988 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 309 | 0.070 |
Why?
|
| Mice | 5 | 2016 | 10846 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 31 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Sulfones | 1 | 2002 | 39 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 75 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2016 | 519 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 374 | 0.040 |
Why?
|
| Animals | 5 | 2016 | 20666 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 167 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3035 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 71 | 0.040 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 851 | 0.030 |
Why?
|
| Humans | 7 | 2019 | 63512 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 52 | 0.030 |
Why?
|
| Female | 5 | 2019 | 32912 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 457 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 575 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 326 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 40 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1120 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1380 | 0.030 |
Why?
|
| Plant Roots | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 525 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 207 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2462 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 612 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 1207 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 897 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 14469 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 16837 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 17641 | 0.020 |
Why?
|
| Vimentin | 1 | 2010 | 18 | 0.020 |
Why?
|
| Keratins | 1 | 2010 | 31 | 0.020 |
Why?
|
| Male | 2 | 2019 | 29927 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 24 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 61 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 80 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 110 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 229 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3770 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5359 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 200 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2010 | 104 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 128 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 279 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 347 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 883 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 6670 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4700 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7855 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5699 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 921 | 0.010 |
Why?
|